EstroBalance with DIM contains the patented, bioavailable form of diindolylmethane. DIM is naturally present in vegetables such as broccoli. One tablet of EstroBalance with DIM is equivalent to approximately two pounds of broccoli. The role of DIM in the body is to support the healthy metabolism of estrogen, which is important for both men and women. EstroBalance with DIM is a patented technology that enhances the absorption and bioavailability of DIM.

Hormones are an important factor in the way the body works. And, when not in balance, their effect can't be underestimated. This includes fatigue, mood swings, occasional PMS, menstrual cramps and difficulty losing weight.

INTRODUCTION
The healthy effects of eating vegetables have been known for many years. It is only recently, however, that scientists have worked to determine which substances in these foods provide specific benefits. Diindolylmethane (DIM) is one of these substances. Because the size and shape of DIM is similar to natural hormones, this food substance, which works through the hormonal system, is a promoter of hormonal balance and overall metabolism.¹

Though discovered over ten years ago, the connection between plant-derived dietary ingredients and estrogen is just beginning to be appreciated. This connection may be helpful in explaining why people living in developed countries, but lacking dietary phytonutrients, suffer disproportionately from hormonal imbalance.² Research has shown that supplemental use of a single cruciferous phytonutrient can support the metabolism of estrogen.^3,4 This change in metabolism has the power to greatly reduce unhealthy estrogen exposure.

Diindolylmethane
Diindolylmethane (DIM), a dietary indole, is a naturally occurring component of Brassica (cruciferous) vegetables, such as cabbage, broccoli, Brussels sprouts, and cauliflower. DIM is formed from Indole-3 carbinol (I3C) after plant enzymes are released by crushing or chewing the vegetable. DIM is also formed directly from I3C, without enzymes, in an acidic environment such as in the stomach, when I3C is taken as a food supplement.^5,6

Hormones
Hormones are substances secreted by specialized cells that affect the metabolism or behavior of other cells possessing receptors for the hormone. Hormones are conveyed throughout the body by the blood. They exert a physiological control effect on other cells in the body.^7-9 Hormones may be hydrophilic (water loving), like insulin, in which case the receptors are on the cell surface or lipophilic (lipid or fat loving), like the steroids, where the receptor can be intracellular. Some problems may be stimulated by hormones, while other problems may be inhibited by hormones.^7,8

Estrogen, progesterone, and testosterone are called sex hormones because they strongly affect the reproductive system. However, they also have many other functions in the body. For example, estrogen helps to maintain healthy bones and skin in both women and men. Likewise, testosterone is present in both men and women, and supports healthy bones and muscles. Testosterone can also improve energy, mood, and libido.¹⁰

Long term exposure to estrogens, in the form of hormone replacement therapy or xenoestrogens (estrogen mimics), is associated with several health risks.^11,12 The ratio of estrogen metabolites (e.g. 2-hydroxyestrone over 16-hydroxyestrone) is an established indicator of hormonal balance in women and men, influencing the health of the breast, endometrium, uterus, cervix, prostate and other tissues.^13-22 Effective estrogen clearance is a growing concern among health care providers, and its implications for gynecologic health and healthy cell development are significant:

• The normal aging process is characterized by increased activity of aromatase enzymes that convert DHEA and testosterone metabolites into estrogen.¹⁴ Modulation of this phenomenon can reduce age-related exposure to excessive estrogen and promote a more favorable balance of estrogen metabolites.

   

• Exposure to exogenous estrogens and estrogen-mimics (xenoestrogens) can cause hormonal overstimulation, leading to imbalances in estrogen metabolites. This may affect the female and male reproductive systems.⁵

   

• Imbalances of estrogen metabolites can lead to a reduction in the efficiency of protective apoptosis (programmed cell death) in various tissues.⁵

Induction and modulation of enzymes regulating hepatic (liver) Phase I and Phase II detoxification enhances the metabolism required for the elimination of various toxic xenobiotics (a chemical substance not produced by the body, and thus foreign to it),^23,24 and restoration of estrogen balance.

HOW DOES IT WORK?
Cruciferous vegetables contain several phytochemicals capable of significantly modifying the metabolism of estrogens. These include indole-3-carbinol (I3C), phenethyl isothiocyanate (PEITC), sulforaphane and diindolylmethane (DIM). All four of these phytochemicals arise from the hydrolysis of glucosinolates, a group of parent compounds that are found in Brassica family vegetables and are responsible for their distinctive flavor. In the body, I3C is converted into DIM, its bioactive form. Despite being rich sources of DIM, it is difficult to consume cruciferous vegetables in sufficient quantities to consistently affect estrogen metabolism or support detoxification enzymes.⁵

In one study, consumption of 500 grams per day of broccoli produced only a minor shift in estrogen metabolism.²⁵ Consumption of larger quantities would be necessary to obtain a desirable level of glucosinolates, and this is problematic because of gastrointestinal side effects.²⁶

I3C and DIM modify cytochrome p450 (CYP) enzyme activity and support detoxification. The current drug-nutrient interactions that have been described for St. John's Wort and grapefruit juice do not apply to EstroBalance with DIM. St. John's Wort causes an increase in the metabolism of various drugs by induction of CYP3A enzymes. Grapefruit juice is an inhibitor of this enzyme system, but does help in the absorption of DIM because these enzymes (CYP3A) are involved in DIM absorption. DIM enhances the activity of the CYP1A enzymes. These are the enzymes that are important in healthy estrogen metabolism.²⁷

Both I3C and DIM have been shown to increase the production of 2-hydroxyestrogen metabolism.⁵ DIM is the most potent inducer of 2-hydroxylase, the enzyme responsible for this beneficial shift in estrogen metabolites.²⁸ DIM induces 2-hydroxyestrone (2OH1) and 2-hydroxyestradiol (2-OH2) in diverse tissues, leading to net inhibition of excessive estrogen stimulation. Once present in the circulation, 2-0H1 and 2-0H2 are metabolized by catechol-O-methyl transferase (COMT), resulting in 2-methoxyestrone and 2-methoxyestradiol. These critical metabolites have been shown to promote healthy cell development in animals and humans.^6,29-41 DIM is the most active and important of the dietary indoles, at least 10 times more potent than its precursor, I3C. DIM is also more beneficial than 13C as a dietary supplement, because I3C may promote CYP metabolism to reactive intermediates. I3C is unstable, reacts unpredictably during storage and digestion, and lacks biologic activity unless converted by the body into DIM.¹⁰

Diindolylmethane is extremely insoluble in both water and lipids, and poorly absorbed without a biodelivery vehicle. EstroBalance with DIM provides an effective delivery system that has undergone testing in animal and clinical settings. Bioavailability testing in animals established at least a tenfold advantage of EstroBalance with DIM over unprocessed DIM.⁴² In clinical testing, supplementation of volunteers with pure, unprocessed DIM did not alter the metabolite ratio. However, repeat testing of the same volunteers at much lower doses using EstroBalance with DIM did beneficially alter the metabolite ratio, favoring an increase of 2-hydroxy over 16-hydroxy estrogen metabolites, promoting metabolism to the desirable 2-methoxy estrogen metabolites.⁴³

EstroBalance with DIM is the first dietary supplement with research that associates changes in estrogen metabolites with indices of health. EstroBalance with DIM supplies a beneficial quantity of DIM to supplement cruciferous vegetables in the diet. Use of DIM in animal studies at hundreds of times the dose provided by EstroBalance with DIM produced no adverse effects.⁴⁴

DIM is less reactive and less of an enzyme inducer than I3C. Doubling the typical dose of I3C from 400 to 800 mg/day can cause unwanted side effects in humans.⁴⁰ No side effects of any sort are seen with DIM even when the typical dose of 150mg/day is tripled to 450 mg/ day.⁴⁵


REFERENCES
 

1. Zeligs MA. Safer Estrogen with Phytonutrition. Townsend Letter for Doctors and Patients. 1999; 189:83-88.
2. Adlercreutz H. Western diet and Western Diseases: Some hormonal and biochemical mechanisms and associations. Scand J Clin Lab Invest. 1990;50(Suppl 21):3-23.
3. Michnovicz JJ, Bradlow HL. Dietary and pharmacological control of estradiol metabolism in humans. Ann NY Acad Sci. 1990;595:291-299.
4. Michnovicz JJ, Bradlow HL. Altered estrogen metabolism and excretion in humans following consumption of indole-3-carbinol. Nutr Cancer. 1991;16:59-66.
5. Zeligs MA. Diet and estrogen status: the cruciferous connection. J Med Foods. 1998;1:67-82.
6. Cover CM, Hsieh SJ, Tran SH. Indole-3-carbinol inhibits the expression of cyclin-dependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. J Biol Chem. 1998;273:3838-3847.
7. Hormone. On-line medical dictionary. Available at: http://www. Graylab.ac.uk/cgi-bin/omd?query=Hormone&action=Search+OMD. Accessed August 28, 2000.
8. Hormone. In: Thomas CL, ed. Taber's Cyclopedic Medical Dictionary. 17th ed. Philadelphia, Pa: F.A. Davis;1993:912.
9. Guyton AC, Hall JE. eds. Textbook of Medical Physiology 9th ed. Philadelphia, Pa: W.B. Saunders Co; 1996:925.
10. Zeligs MA, Connelly AS. All About DIM. New York, NY: Avery; 2000:9.
11. Cooper RL, Kavlock FIJ. Endocrine disrupters and reproductive development: a weight-of evidence overview. J Endocrinol. 1997;152:159-166.
12. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995;332:1589-1593.
13. Sepkovic DW, Bradlow HL, Ho G, et al. Estrogen metabolite ratios and risk assessment of hormone-related cancers: Assay validation and prediction of cervical cancer risk. Ann NY Acad Sci. 1995;768:312-316.
14. Bulun SE, Simpson ER. Competitive reverse transcription-polymerase chain reactor analysis indicates that levels of aromatese cytochrome P450 transcripts in adipose tissue of buttocks, thighs, and abdomen of women increase with advancing age. J Clin Endocrinol Metab. 1994;78:428-432.
15. Schneider J, Kinne D, Fracchia A, Pierce V, Anderson KE, Bradlow HL, Fishman J. Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc Natl Acad Sci USA. 1982;79:3047-3051.
16. Zumoff B, Fishman J, Cassouto J, Hellman L, Gallagher TF. Estradiol transformation in men with breast cancer. J Clin Endocrinol Metab. 1966;26:960-966.
17. Fishman J, Schneider J, Hershcope RJ, Bradlow HL. Increased estrogen-16 alpha-hydroxylase activity in women with breast and endometrial cancer. J Steroid Biochem. 1984;20:1077-1081.
18. Lahita RG, Bradlow HL, Kunkel HG, Fishman J. Alterations of estrogen metabolism in systemic lupus erythematosus. Arthritis Rheum. 1979;22:1195-1198.
19. Nakhla AM, Khan MS, Romas NP, Rosner W. Estradiol causes the rapid accumulation of cAMP in human prostate. Proc Natl Acad Sci USA. 1994;91:5402-5405.
20. Nakhla AM, Romas NA, Rosner W. Estradiol activates the prostate androgen receptor and prostate-specific antigen secretion through the intermediacy of sex hormone-binding globulin. Biol Chem. 1997;272:6838-6841.
21. Farnsworth WE. Roles of estrogen and SHBG in prostate physiology. Prostate. 1996;28:17-23.
22. Yue TL, Wang X, Louden CS, et al. 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression. Mol Pharmacol. 1997;51:951-962.
23. Xenobiotic. In: Thomas CL, ed. Taber's Cyclopedic Medical Dictionary. 17th ed. Philadelphia, Pa: F.A. Davis; 1993: 2170.
24. Xenobiotics. On-line medical dictionary. Available at: http://www. Graylab.ac.uk/cgi-bin/omd?query=xenobiotics&action=Search+OMD. Accessed August 28, 2000.
25. Kall MA, Vang O, Clausen J. Effects of dietary broccoli on human in vivo drug metabolizing enzymes: evaluation of caffeine, oestrone and chlorzoxazone metabolism. Carcinogenesis. 1996; 17:793-799.
26. de Groot AP, Willems MI, de Vos RH. Effects of high levels of Brussels sprouts in the diet of rats. Food Chem Toxicol. 1991:29:829-837.
27. Michael A. Zeligs MD. Founder and CEO of BioResponse, LLC. Boulder, Co. Written communication (electronic mail). October 4, 2000.
28. Jellinck PH, Forkert PG, Riddick DS, Okey AB, Michnovicz JJ, Bradlow HL. Ah receptor binding properties of indole carbinols and induction of hepatic estradiol hydroxylation. Biochem Pharmacol. 1993;45:1129-1136.
29. Bradlow HL, Michnovicz J, Telang NT, Osborne MP. Effects of dietary indole-3carbinol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis. 1991; 12:1571-1574.
30. Bradlow HL, Sepkovic DW, Telang NT, Osborne MP. Indole-3-carbinol. A novel approach to breast cancer prevention. Ann NY Acad Sci. 1995; 768:180-2000.
31. Chen I, McDougal A, Wang F, Safe S. Aryl hydrocarbon receptor-mediated anti-estrogenic and antitumorigenic activity of diindolylmethane. Carcinogenesis. 1998;19:1631-1639.
32. Chen I, Safe S, Bjeldanes L. Indole-3-carbinol and diindolylmethane as aryl hydrocarbon (Ah) receptor agonists and antagonists in T47D human breast cancer cells. Biochem Pharmacol. 1996;51:1069-1076.
33. Ge X, Yannai S, Rennert G, Gruener N, Fares FA. 3,3'-Diindolylmethane induces apoptosis in human cancer cells. Biochem Biophys Res Commun. 1996;228:153-158.
34. Grubbs CJ, Steele VE, Casebolt T. Chemoprevention of chemically-induced mammary carcinogenesis by indole3-carbinol. Anticancer Res. 1995;15:709-716.
35. Kojima T, Tanaka T, Mori H. Chemoprevention of spontaneous endometrial cancer in female Donryu rats by dietary indole-3-carbinoi. Cancer Res. 1994;54:1446-1449.
36. Lake BG, Tredger JM, Renwick AB, Barton PT, Price RJ. 3,3'-Diindoly[methane induces CYPlA2 in cultured precision-cut human liver slices. Xenobiotica. 1998;28:803-811.
37. Niwa T, Swaneck G, Bradlow HL. Alterations in estradiol metabolism in MCF-7 cells induced by treatment with indole-3 carbinol and related compounds. Steroids. 1994;59:523-527.
38. Stresser DM, Bjeldanes LF, Bailey GS, Williams DE. The anticarcinogen 3,3'-diindoly1methane is an inhibitor of cytochrome P-450. Biochem Toxicol. 1995; 10:191-201.
39. Telang NT, Katdare M, Bradlow HL, Osborne MP, Fishman J. Inhibition of proliferation and modulation of estradiol metabolism: novel mechanisms for breast cancer prevention by the phytochemical indole-3-carbinol. Proc Soc Exp Biol Med. 1997;216:246-252.
40. Tiwari RK, Guo L, Bradlow HL, Telang NT, Osborne MP. Selective responsiveness of human breast cancer cells to indole-3-carbinol, a chemopreventive agent. J Natl Cancer Inst. 1994;86:126-31.
41. Rosen CA, Woodson GE, Thompson JW, Hengesteg AP, Bradlow HL. Preliminary results of the use of indole-3-carbinol for recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg. 1998;118:810-815.
42. Animal Bioavailability Studies. Data on file, BioResponse, LLC, 1998.
43. Human Bioavailability Studies. Data on File, BioResponse, L.L.C. 1998.
44. McDanell R, McLean AE, Hanley AB, Heaney RK, Fenwick GR. Differential induction of mixed-function oxidase (MFO) activity in rat liver and intestine by diets containing processed cabbage: correlation with cabbage levels of glucosinolates and glucosinolate hydrolysis products. Food Chem Toxicol. 1987;25:363-368.
45. Zeligs MA, Zeligs ET, Albert D. An Open Label Study of BioResponse DIM for promotion of weight loss during a modified carbohydrate diet. Data on File, BioResponse, LLC, 1999.
46. Michael A. Zeligs MD. Founder and CEO of BioResponse, LLC. Boulder, Co. Written communication (electronic mail). October 4, 2000.